US 11,666,659 B2
Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein PV-1, preparation and use thereof
Xiaoqi Song, Suzhou (CN); Zui Chen, Suzhou (CN); Hongqun Hu, Suzhou (CN); Guifang Zhou, Suzhou (CN); Jinling Fan, Suzhou (CN); and Qunmin Zhou, Suzhou (CN)
Assigned to HUALAN GENETIC ENGINEERING CO., LTD., Xinxiang (CN)
Appl. No. 16/978,198
Filed by HUALAN GENETIC ENGINEERING CO., LTD., Xinxiang (CN)
PCT Filed Sep. 27, 2018, PCT No. PCT/CN2018/107809
§ 371(c)(1), (2) Date Sep. 4, 2020,
PCT Pub. No. WO2019/184282, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 201810266295.5 (CN), filed on Mar. 30, 2018.
Prior Publication US 2021/0000969 A1, Jan. 7, 2021
Int. Cl. A61K 47/68 (2017.01); C07K 16/22 (2006.01); C07K 16/42 (2006.01); C12N 15/10 (2006.01); C12N 15/63 (2006.01)
CPC A61K 47/6803 (2017.08) [C07K 16/22 (2013.01); C07K 16/4241 (2013.01); C12N 15/101 (2013.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)] 16 Claims
 
1. A monoclonal antibody or a derivative thereof specifically binding to human plasmalemma vesicle-associated protein, comprising a first variable region and a second variable region,
wherein the first variable region is an antibody light chain variable region comprising antigen complementarity-determining regions CDR1, CDR2 and CDR3 having amino acid sequences as set forth in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, respectively; and
wherein the second variable region is an antibody heavy chain variable region comprising antigen complementarity-determining regions CDR1, CDR2 and CDR3 having amino acid sequences as set forth in SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, respectively, and
wherein the derivative is a Fab fragment an Fv fragment a single-chain antibody, a bispecific antibody, an antibody-drug conjugate, or a chimeric antigen receptor T-cell.